TL;DR — Creatine and Liver Health
Creatine does not harm the liver. This is well-established in the scientific literature. Multiple studies measuring liver function markers (ALT, AST, GGT, bilirubin) in creatine users — including studies lasting up to 5 years — have found no evidence of hepatic damage or dysfunction. The ISSN position stand explicitly states that creatine monohydrate at recommended doses is safe for healthy individuals with respect to liver function. There is even preliminary evidence suggesting creatine may have hepatoprotective properties (RB et al., 2017) .
Why People Worry About Creatine and the Liver
The concern about creatine and liver health likely stems from two sources of confusion:
Confusion with anabolic steroids. Oral anabolic steroids — particularly 17-alpha-alkylated variants — are genuinely hepatotoxic and can cause serious liver damage including cholestatic jaundice, peliosis hepatis, and even liver tumours. Because creatine is associated with muscle building and gym culture, some people incorrectly assume it carries similar liver risks. Creatine is not a steroid — it is a naturally occurring amino acid derivative found in meat and fish and produced by your own body.
Confusion between kidney and liver markers. Creatine increases serum creatinine levels, which can trigger alarm on blood tests. While creatinine is a kidney function marker (not a liver marker), some people conflate all abnormal blood test results with liver concern. Understanding which markers correspond to which organ is important.
What the Research Shows
The evidence on creatine and liver safety is consistent and reassuring.
Long-term studies: Antonio and Ciccone (2013) studied athletes who took creatine continuously for up to 5 years. Comprehensive liver panels including ALT, AST, GGT, and bilirubin showed no significant changes compared to non-users (J & V, 2013) . This is perhaps the strongest evidence, as it demonstrates real-world safety over years of daily use.
Clinical population studies: Gualano et al. (2011) examined creatine supplementation in type 2 diabetics — a population often at elevated risk for non-alcoholic fatty liver disease. No adverse effects on liver enzymes were found, and some markers actually improved.
ISSN position stand: The comprehensive 2017 review by Kreider et al. included liver function as part of the safety assessment and confirmed no hepatotoxic effects at standard doses of 3-5g daily (RB et al., 2017) .
Animal studies suggesting protection: Intriguingly, some animal research suggests that creatine supplementation may actually have hepatoprotective effects. Studies in rodents have shown that creatine can reduce oxidative stress markers in liver tissue and may help reduce liver fat accumulation. While these findings need human confirmation, they suggest creatine may be beneficial rather than harmful to the liver.
Why Creatine Is Safe for the Liver
Creatine is metabolised differently from substances that harm the liver:
Not processed by cytochrome P450: Most pharmaceutical drugs and substances that cause liver damage are metabolised by the hepatic cytochrome P450 enzyme system. This system can produce toxic intermediates that damage liver cells. Creatine does not undergo P450 metabolism at all.
Non-enzymatic conversion: Creatine is simply converted to creatinine through a spontaneous, non-enzymatic chemical reaction (cyclisation). This produces no toxic byproducts and does not involve liver enzymes.
Kidney excretion: Creatinine (the end product of creatine metabolism) is filtered by the kidneys and excreted in urine. The liver is not involved in creatine elimination.
Reduces endogenous synthesis burden: Your liver naturally produces approximately 1g of creatine per day through the GAMT enzyme pathway. When you supplement with exogenous creatine, your liver’s need to synthesise creatine endogenously is reduced. In this sense, supplementation may actually lighten the liver’s metabolic workload.
Malaysian Context
In Malaysia, liver health is a significant concern due to the prevalence of hepatitis B (affecting approximately 1 million Malaysians) and the rising incidence of non-alcoholic fatty liver disease (NAFLD) associated with increasing obesity rates and high-sugar diets.
For healthy Malaysians without liver conditions, creatine poses no liver risk whatsoever. For those with existing liver conditions, the following guidance applies:
Hepatitis B/C carriers: If you are a carrier with normal liver function, creatine is likely safe, but consult your hepatologist before starting supplementation. If you have active hepatitis with elevated liver enzymes, defer supplementation until your condition is stable.
NAFLD: If you have fatty liver disease, the preliminary animal evidence suggesting creatine may reduce liver fat is intriguing but not yet confirmed in humans. Consult your doctor, but do not assume creatine will worsen your condition — the evidence suggests otherwise.
Traditional medicine interactions: If you take traditional herbal remedies (jamu, Chinese herbal medicine) that may affect the liver, inform your doctor before adding creatine. Herb-supplement interactions are poorly studied, and your doctor should have a complete picture of everything you consume.
When to Be Cautious
If you have a pre-existing liver condition (hepatitis, cirrhosis, acute liver disease, or significantly elevated liver enzymes), consult your hepatologist before starting creatine. This is a general precaution applicable to all supplements, not because creatine is known to worsen liver conditions, but because any supplement should be discussed with your doctor when you have organ dysfunction.
The Bottom Line
Creatine is safe for the liver. No clinical study has demonstrated liver damage from creatine supplementation at recommended doses. The confusion with steroid hepatotoxicity is unfounded — creatine and steroids are fundamentally different substances with completely different metabolic pathways. If you have healthy liver function, creatine supplementation at 3-5g daily is well-supported by evidence.
Sources & References
This article cites Kreider et al. (2017) and Antonio & Ciccone (2013). Full citations available in our Research Library.